In June 2023, POINT Biopharma and AdvanCell collaborated on developing a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network for 212Pb-labeled radioligands by ...
The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)” will be presented as a part of ...
Molecular Partners and Orano Med expand collaboration to develop ten 212Pb-Radio-DARPin therapy candidates, initiating clinical trials in 2025. Molecular Partners AG and Orano Med have expanded ...
The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations. For more information, please visit the Company's website at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback